Pscilly

Small trial reports higher quit rates with psilocybin and counseling

By · Published · Updated

A pilot randomized clinical trial at Johns Hopkins Bayview Medical Center in Baltimore compared psilocybin-assisted treatment with nicotine patches for smoking cessation. The study included 82 psychiatrically healthy adult smokers, whose average age was 47.6. Researchers collected data between January 20, 2015, and May 8, 2023; 68 participants completed the six-month follow-up. The report was published in JAMA Network Open. Participants were assigned to one high dose of psilocybin or to begin an eight-to-ten-week nicotine patch course on their planned quit date. Both groups also received a 13-week cognitive behavioral therapy program. According to the study, 17 people in the psilocybin group, or 40.5%, met the measure of prolonged abstinence at six months, compared with four people, or 10%, in the patch group. Seven-day abstinence at that follow-up was reported for 52.4% and 25% of the groups, respectively. The researchers described the work as a pilot trial, and participants and investigators knew which treatment was assigned. The study also allowed an optional crossover after its primary endpoint, and 14 participants did not complete the six-month follow-up. No serious adverse events were attributed to either treatment in the trial. The findings are a comparison from this particular study, not a recommendation to use psilocybin. For mushroom readers, the report adds to research examining psilocybin in a structured therapeutic setting, while leaving questions for further study.

Published
February 3, 2026
Place
Baltimore, MD
Source
pubmed.ncbi.nlm.nih.gov

Nearby